<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">r-n-j</journal-id><journal-title-group><journal-title xml:lang="ru">Российский неврологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian neurological journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2658-7947</issn><issn pub-type="epub">2686-7192</issn><publisher><publisher-name>МИА</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.30629/2658-7947-2025-30-1-46-50</article-id><article-id custom-type="elpub" pub-id-type="custom">r-n-j-665</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ИССЛЕДОВАНИЯ И КЛИНИЧЕСКИЕ НАБЛЮДЕНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL RESEARCHES AND CASE REPORTS</subject></subj-group></article-categories><title-group><article-title>Взаимосвязь развития когнитивных расстройств и полиневропатии на фоне химиотерапии</article-title><trans-title-group xml:lang="en"><trans-title>The relationship between the development of cognitive disorders and polyneuropathy on the background of chemotherapy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3152-8380</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Баландин</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Balandin</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пермь</p></bio><bio xml:lang="en"><p>Perm</p></bio><email xlink:type="simple">balandinnauka@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-1292-6019</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Овчинникова</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Ovchinnikova</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пермь</p></bio><bio xml:lang="en"><p>Perm</p></bio><email xlink:type="simple">katerinerowe@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4856-9066</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Баландина</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Balandina</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пермь</p></bio><bio xml:lang="en"><p>Perm</p></bio><email xlink:type="simple">balandina_ia@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Пермский государственный медицинский университет имени академика Е.А. Вагнера<country>Россия</country></aff><aff xml:lang="en">E.A.Vagner Perm State Medical University<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>10</day><month>05</month><year>2025</year></pub-date><volume>30</volume><issue>1</issue><fpage>46</fpage><lpage>50</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Баландин А.А., Овчинникова Е.А., Баландина И.А., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Баландин А.А., Овчинникова Е.А., Баландина И.А.</copyright-holder><copyright-holder xml:lang="en">Balandin A.A., Ovchinnikova E.A., Balandina I.A.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.r-n-j.com/jour/article/view/665">https://www.r-n-j.com/jour/article/view/665</self-uri><abstract><p>Введение. Химиотерапия — один из ключевых методов лечения в онкологии. Цитостатики не обладают избирательной активностью к клеткам опухолей и оказывают токсическое влияние на здоровые ткани. Негативным побочным действием цитостатиков являются поражения нервной ткани. Наиболее распространенные –постхимиотерапевтическая полиневропатия и когнитивные нарушения.Цель работы: проанализировать взаимоотношение развития когнитивных расстройств и полиневропатии у онкологических пациентов на фоне химиотерапии.Материал и методы. Работа проведена в отделении химиотерапии и основана на результатах обследования 60 пациенток со злокачественным новообразованием молочной железы. В исследование вошли женщины в возрасте от 32 до 58 лет, в анамнезе которых отсутствовали иные заболевания и состояния, способные провоцировать расстройства периферической и центральной нервной системы. Пациентки были разделены на 2 группы: прошедшие менее 10 курсов химиотерапии и более 10 курсов химиотерапии. Для оценки выраженности симптомов полиневропатии использовали шкалу Neuropathy Symptom Score (NSS). Оценку когнитивных функций проводили с помощью шкал Mini-Mental State Examination (MMSE).Результаты. По шкале NSS между двумя группами имелись статистически достоверные различия (p &lt; 0,05). По шкале MMSE статистически достоверных различий между первой и второй группами не выявлено. Получена положительная корреляция между дебютом полиневропатии и когнитивными расстройствами (ρ = 0,8975).Заключение. Химиотерапевтические препараты оказывают системное воздействие на нервную ткань, и чем раньше они повреждают периферическую нервную систему, т.е. чем раньше возникает полиневропатия, тем скорее проявляется поражение центральной нервной системы (энцефалопатия).</p></abstract><trans-abstract xml:lang="en"><p>Introduction. Chemotherapy is one of the key methods of treatment in oncology. Cytostatics do not have selective activity to tumor cells and have a toxic effect on healthy tissues. A negative side effect of cytostatics is damage to the nervous tissue. The most common are post–chemotherapeutic polyneuropathy and cognitive impairment.Aim. To analyze the relationship between the development of cognitive disorders in cancer patients and the occurrence of polyneuropathy.Material and methods. The work was carried out in the chemotherapy department and is based on the results of examination of 60 patients with malignant neoplasm of the breast. The study included women aged 32 to 58 years, in whose anamnesis there were no other diseases and conditions capable of provoking disorders of the peripheral and central nervous system. The patients were divided into 2 groups: those who had undergone less than 10 courses of chemotherapy and more than 10 courses of chemotherapy. The Neuropathy Symptom Score (NSS) scale was used to assess the severity of polyneuropathy symptoms. The severity of cognitive disorders was assessed using the Mini- Mental State Examination (MMSE) scale.Results. Statistically significant differences were found between the two groups on the NSS scale (p &lt; 0.05). According to the MMSE scale, there were no statistically significant differences between the first and second groups. A positive correlation was found between the onset of polyneuropathy and cognitive disorders (p = 0.8975).Conclusions. Chemotherapeutic drugs have a systemic effect on nervous tissue and the earlier they damage peripheral nervous tissue, that is, the earlier polyneuropathy occurs, the sooner damage to the central nervous system (encephalopathy) manifests itself.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>химиотерапия</kwd><kwd>цитостатики</kwd><kwd>энцефалопатия</kwd><kwd>когнитивные нарушения</kwd><kwd>полиневропатия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chemotherapy</kwd><kwd>cytostatics</kwd><kwd>encephalopathy</kwd><kwd>cognitive impairment</kwd><kwd>polyneuropathy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Bordoni B., Urbinati S., Tosoni A., Labanti G., Brandes A. Cardiologic evaluation of patients undergoing chemotherapy. Monaldi Arch Chest Dis. 2014;82(2):68–74. https://doi.org/10.4081/monaldi.2014.46.</mixed-citation><mixed-citation xml:lang="en">Bordoni B., Urbinati S., Tosoni A., Labanti G., Brandes A. Cardiologic evaluation of patients undergoing chemotherapy. Monaldi Arch Chest Dis. 2014;82(2):68–74. https://doi.org/10.4081/monaldi.2014.46.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Tierney A.J., Leonard R.C., Taylor J., Closs S.J., Chetty U., Rodger A. Side effects expected and experienced by women receiving chemotherapy for breast cancer. British Medical Journal. 1991;302:272. https://doi.org/10.1136/bmj.302.6771.272.</mixed-citation><mixed-citation xml:lang="en">Tierney A.J., Leonard R.C., Taylor J., Closs S.J., Chetty U., Rodger A. Side effects expected and experienced by women receiving chemotherapy for breast cancer. British Medical Journal. 1991;302:272. https://doi.org/10.1136/bmj.302.6771.272.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Razvi Y., Chan S., McFarlane T., McKenzie E., Zaki P., DeAngelis C., Pidduck W., Bushehri A., Chow E., Jerzak K.J. ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer. 2019;27(1):87–95. https://doi.org/10.1007/s00520-018-4464-y.</mixed-citation><mixed-citation xml:lang="en">Razvi Y., Chan S., McFarlane T., McKenzie E., Zaki P., DeAngelis C., Pidduck W., Bushehri A., Chow E., Jerzak K.J. ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer. 2019;27(1):87–95. https://doi.org/10.1007/s00520-018-4464-y.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Shankar A., Roy S., Abhidha M., Julka P.K., Rath G.K. Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Patients. Asian Pac J Cancer Prev. 2015;16(15):6207–13. https://doi.org/10.7314/apjcp.2015.16.15.6207.</mixed-citation><mixed-citation xml:lang="en">Shankar A., Roy S., Abhidha M., Julka P.K., Rath G.K. Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Patients. Asian Pac J Cancer Prev. 2015;16(15):6207–13. https:// doi.org/10.7314/apjcp.2015.16.15.6207.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Schwartzberg L. Chemotherapy-induced nausea and vomiting: state of the art in 2006. J Support Oncol. 2006;4:3–8. https://popline.org/node/601652.</mixed-citation><mixed-citation xml:lang="en">Schwartzberg L. Chemotherapy-induced nausea and vomiting: state of the art in 2006. J Support Oncol. 2006;4:3–8. https:// popline.org/node/601652.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Rodwin R.L., Siddiq N.Z., Ehrlich B.E., Lustberg M.B. Biomarkers of Chemotherapy-Induced Peripheral Neuropathy: Current Status and Future Directions. Front Pain Res. 2022;3:864910. https://doi.org/10.3389/fpain.2022.864910.</mixed-citation><mixed-citation xml:lang="en">Rodwin R.L., Siddiq N.Z., Ehrlich B.E., Lustberg M.B. Biomarkers of Chemotherapy-Induced Peripheral Neuropathy: Current Status and Future Directions. Front Pain Res. 2022;3:864910. https://doi.org/10.3389/fpain.2022.864910.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Gießen-Jung C., Von Baumgarten L. Peripheral neuropathy as a side effect of chemotherapy and targeted therapy. Dtsch Med Wochenschr. 2018;113(13):970–978. https://doi.org/10.1055/s-0043-120839.</mixed-citation><mixed-citation xml:lang="en">Gießen-Jung C., Von Baumgarten L. Peripheral neuropathy as a side effect of chemotherapy and targeted therapy. Dtsch Med Wochenschr. 2018;113(13):970–978. https://doi.org/10.1055/s-0043-120839.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Иозефи Д.Я., Винидченко М.А., Демченко Н.С. Проблема токсической энцефалопатии, ассоциированной с химиотерапией у онкологических больных, обзор возможностей магнитно-резонансной визуализации и нейроонкологического мониторинга. Главврач Юга России. 2017;3(56):43–47.</mixed-citation><mixed-citation xml:lang="en">Iozefi D.YA., Vinidchenko M.A., Demchenko N.S. The problem of toxic encephalopathy associated with chemotherapy in cancer patients, a review of the capabilities of magnetic resonance imaging and neuro-oncological monitoring. Glavvrach Yuga Rossii. 2017;3 (56):43–47 (In Russ.). https://cyberleninka.ru/article/n/problema-toksicheskoy-entsefalopatii-assotsiirovannoy-s-himioterapiey-u-onkologicheskih-bolnyh-obzor-vozmozhnosteymagnitno.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Verstappen C.C.P., Heimans J.J., Hoekman K. Neurotoxic Complications of Chemotherapy in Patients with Cancer. Drugs. 2003;63:1549–1563. https://doi.org/10.2165/00003495-200363150-00003.</mixed-citation><mixed-citation xml:lang="en">Verstappen C.C.P., Heimans J.J., Hoekman K. Neurotoxic Complications of Chemotherapy in Patients with Cancer. Drugs. 2003;63:1549–1563. https://doi.org/10.2165/00003495-200363150-00003.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Bhagra A., Rao R.D. Chemotherapy-induced neuropathy. Curr Oncol Rep. 2007;9(4):290–9. https://doi.org/10.1007/s11912-007-0036-x.</mixed-citation><mixed-citation xml:lang="en">Bhagra A., Rao R.D. Chemotherapy-induced neuropathy. Curr Oncol Rep. 2007;9(4):290–9. https://doi.org/10.1007/s11912-007-0036-x.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Graham R.C., Hughes R.A. A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. J Neurol Neurosurg Psychiatry. 2006;77(8):973–6. https://doi.org/10.1136/jnnp.2005.081547.</mixed-citation><mixed-citation xml:lang="en">Graham R.C., Hughes R.A. A modifi ed peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. J Neurol Neurosurg Psychiatry. 2006;77(8):973–6. https://doi.org/10.1136/jnnp.2005.081547.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Yoelin A.B., Saunders N.W. Score Disparity Between the MMSE and the SLUMS. Am J Alzheimers Dis Other Demen. 2017;32(5):282–288. https://doi.org/10.1177/1533317517705222.</mixed-citation><mixed-citation xml:lang="en">Yoelin A.B., Saunders N.W. Score Disparity Between the MMSE and the SLUMS. Am J Alzheimers Dis Other Demen. 2017;32(5):282–288. https://doi.org/10.1177/1533317517705222.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Zajączkowska R., Kocot-Kępska M., Leppert W., Wrzosek A., Mika J., Wordliczek J. Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. Int. J. Mol. Sci. 2019;20(6):1451. https://doi.org/10.3390/ijms20061451.</mixed-citation><mixed-citation xml:lang="en">Zajączkowska R., Kocot-Kępska M., Leppert W., Wrzosek A., Mika J., Wordliczek J. Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. Int. J. Mol. Sci. 2019;20(6):1451. https:// doi.org/10.3390/ijms20061451.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
